- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aerie Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 376 staff and has a trailing 12-month revenue of around $213.9 million.
|Latest market close||$0.00|
|52-week range||$4.81 - $15.37|
|50-day moving average||$15.19|
|200-day moving average||$10.24|
|Wall St. target price||$15.35|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.47|
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2022-12-02
|1 week (2023-03-17)||nan%|
|1 month (2023-02-24)||nan%|
|3 months (2022-12-24)||nan%|
|6 months (2022-09-28)||-100.00%|
|1 year (2022-03-25)||-100.00%|
|2 years (2021-03-26)||-100.00%|
|3 years (2020-03-27)||13.05|
|5 years (2018-03-28)||53.75|
|Revenue TTM||$213.9 million|
|Gross profit TTM||$167.3 million|
|Return on assets TTM||-4.59%|
|Return on equity TTM||-2255.01%|
|Market capitalisation||$753.6 million|
TTM: trailing 12 months
We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $4.81 up to $15.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is -0.062. This would suggest that Aerie Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aerie Pharmaceuticals has bucked the trend.
Aerie Pharmaceuticals, Inc. , a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.